Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Inclusion Criteria: * Men and women aged 18 years and older. The lower age limit may be higher if legally required in the participating country * Women of childbearing potential can only be included in the study if a pregnancy test is negative and if they agree to use adequate contraception when sexually active * Subjects with worsening chronic heart failure requiring emergency presentation to hospital and treatment with intravenous diuretics at hospital * Subjects with clinical diagnosis of chronic heart failure (CHF) either ischemic or non ischemic, New York Heart Association (NYHA) functional class II-IV * Subjects with type 2 diabetes mellitus and / or * Subjects with 30 mL/min/1.73m\^2 \</= eGFR \</= 60 mL/min/1.73m\^2 (MDRD, Modification of Diet in Renal Disease Study Group) at screening * Left ventricular ejection fraction (LVEF) \</= 40% * Blood potassium \</= 5.0 mmol/L at screening * Systolic blood pressure \>/= 90 mmHg without signs and symptoms of hypotension at the screening visit Exclusion Criteria: * Acute de-novo heart failure or acute inflammatory heart disease, e.g. acute myocarditis * Acute coronary syndrome (ACS) in last 30 days prior to screening * Cardiogenic shock * Valvular heart disease requiring surgical intervention during the course of the study * Stroke or transient ischemic cerebral attack in the last 3 months prior to the screening visit * Concomitant treatment with any mineralocorticoid receptor antagonist (MRA), renin inhibitor, or potassiu…